GENESIS Biomed and GENESIS Ventures - Corporate Presentation March 2020
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
GENESIS Biomed and GENESIS Ventures
Corporate Presentation
March 2020
Please contact us at:
Baldiri Reixac 4, 08028 Barcelona
Velázquez 25, 2º A, 28001 Madrid
contact@genesis-biomed.com
+34 93 403 58 53
GENESIS Biomed - Corporate Presentation 1
01
Corporate presentation GENESIS Biomed
GENESIS Biomed - Corporate Presentation 2
01 Corporate Presentation of GENESIS Biomed
Who are we?
GENESIS Biomed is a consultancy firm in the biomedical healthcare sector
specialized in providing consulting services to spin-off and start-up
companies, entrepreneurs and research centers.
Based in our expertise we help entrepreneurs and researchers to shape
their business plan and we support them in the private fundraising
process. We have raised >45 M€ in the last years.
We are Associate Partner at EIT Health and we are currently working in 7
EIT Health projects with TOP EU institutions.
Our expertise domains are biopharmaceutical, biotechnological, medical
devices, in vitro diagnostic, nutraceutical and cosmetic. With more than
20 years of expertise in the healthcare sector, we are born in May 2017
and we are located in the Barcelona Science Park.
In addition, the company owns GENESIS Ventures, a new fund sized in 2,0
M€ that invests in early stage research projects in the biomedical field,
with the aim to accelerate their development and reach key value
milestones to found the company and attract a first round of investment
from other venture funds.
GENESIS Biomed - Corporate Presentation 3
01 Corporate Presentation of GENESIS Biomed
Our locations: Barcelona and Madrid
We are glad to announce that in
September 2019 we have open our
new offices located at Velázquez 25,
Madrid.
Located in the real center of Madrid,
our new offices will allow us to work
closely with the clients we have in
Madrid area.
In the coming weeks we will hire a
manager and two consultants for our
Madrid Office.
GENESIS Biomed HQ
We will keep our Barcelona staff in 10 Madrid Office
members, and GENESIS CEO will be Barcelona Science Park, Tower I
Calle de Velázquez 25, 2º A
working part time in both offices. Baldiri Reixac 4
28001 Madrid
08028 Barcelona
GENESIS Biomed - Corporate Presentation 4
01 Corporate Presentation of GENESIS Biomed
Our portfolio of services
1 Business Plan 2 Private Fundraising 3 Interim CEO
Preparation of business plans for spin-off or Definition of the fundraising strategy. Selection For those start-up companies with an
start-up companies, taking into account market, of private investors among a wide personal incomplete team. Serving as CEO and leading
positioning, regulatory, development, IP, team network and assistance in the fundraising and the Project until identifying and hiring a full-
and financials. negotiation. time CEO.
4 Strategic follow-up and supervision of current projects – For those companies developing a project after a first capital round,
continuous supervision and support in the strategic decision making of the company, serving as Board observer if needed.
5 Market Analysis 6 Regulatory and Development Plan 7 Partners in EIT Health and H2020
Preparation of market and competitors analysis Preparation of regulatory roadmaps including Participation in European consortiums as
using robust databases, knowledge regulatory strategy and development plans for proactive partners, leading the business,
management tools and fieldwork (interviews biopharma, medtech, diagnostic, nutra and regulatory and commercial work packages, in
and focus groups). cosmetic. EIT Health, H2020, FTI and SME-2
8 Business Development
9 Strategic Plan 10 Training & Academy
For companies and research centres. Preparation of strategic plans for research For hospitals and research centres.
In-licensing and out-licensing activities. Well centres and companies, including Provide general knowledge in biomedical
established BD process built in the last 10 years internal/external diagnostic, vision, strategic entrepreneurship and technology transfer to
+ wide network of contacts. objectives and action plan. researchers and institutions
GENESIS Biomed - Corporate Presentation 5
01 Corporate Presentation of GENESIS Biomed
Our value proposition in fundraising projects: from the Scientific case to the Investment case
Investment case In the projects related to fundraising, we always start from the
Scientific Case, always excellent that comes from the Research
Group.
Business case We convert it into a Business Case, that is containing all the
aspects to be considered in a Business Plan.
Finally, creating a team between GENESIS Biomed and the
Research Group, we start a process that helps the investors to
Scientific create their Investment case that provides them support in the
case decision making.
GENESIS Biomed - Corporate Presentation 6
01 Corporate Presentation of GENESIS Biomed
Participation in EU projects as proactive partners
1 Preparation of Business Plan and Design of Business Model
2 Market research and market analysis including fieldwork
3 Implantation Plan and Market Access Plan
4 Commercialization and Exploitation Plan
5 Regulatory roadmap and Regulatory development activities
6 Business Development for Licensing / M&A
Currently working in 12 EU funded projects. We become very proactive partners in the preparation of the proposal
and in the hearings. We are also a high proactive business partner during the development of the project.
GENESIS Biomed - Corporate Presentation 7
01 Corporate Presentation of GENESIS Biomed
GENESIS Biomed becomes EIT Health Associate Partner
Innovation Pillar Acceleration Pillar
GENESIS Biomed will apply to the appropriate
GENESIS Biomed can contribute to take part as a
calls in which our expertise can contribute for
consortium member in Innovation by Ideas or
the Pillar, such as bootcamps, Market Coach
Innovation by Design projects.
Network, Investors network, Crowdfunding
platform, Catapult, etc.
We have become Associate The main tasks to be carried out will be:
Partner • Business plans
at EIT Health • Business coaching
on May 14th 2018 • Commercialization Campus Pillar
• Business development
• Preparation of WP0 We can also contribute in Campus projects by
We have also become
• Etc preparing Sustainability Plans or Bootcamps.
Members of the
Spanish Management Board
at EIT Health
GENESIS Biomed - Corporate Presentation 8
01 Corporate Presentation of GENESIS Biomed
EIT Health, the main biomedical European network with TOP companies and institutions
Our presence in EIT
Health as Associate
partner allows us to
collaborate with TOP
international institutions
In the last months we
have started 8
international projects
GENESIS Biomed - Corporate Presentation 9
01 Corporate Presentation of GENESIS Biomed
Our current client portfolio (1/3)
Spin-off and start-up Big & mid-size
GENESIS Biomed - Corporate Presentation 1001 Corporate Presentation of GENESIS Biomed
Our current client portfolio (2/3)
Academia & Research
GENESIS Biomed - Corporate Presentation 1101 Corporate Presentation of GENESIS Biomed
Our current client portfolio (3/3)
Healthcare Investors Institutional
GENESIS Biomed - Corporate Presentation 1201 Corporate Presentation of GENESIS Biomed
GENESIS team @ Barcelona Office: 11 very committed and passionate people
Josep Lluís Falcó Natalia de la Figuera Jordi Ortiz Carles Taulé Berta Borràs Mireia Samitier
Managing partner & CEO Managing partner & COO Senior Consultant Consultant Consultant Consultant
Chemist PhD, MBA Chemist PhD, PMP® Chemist Pharmacist Biotech. and Biochemist Biologist
Gisela Gallego Anna Miró Alberto Rodríguez Mariona Costa Teresa Bau
Consultant Consultant Consultant trainee Consultant trainee Comms Manager
Biotechnologist Biomedical Sciences Biotechnologist Biotechnologist Journalist & Digital MKT
GENESIS Biomed - Corporate Presentation 1301 Corporate Presentation of GENESIS Biomed
A highly committed team
Josep Lluís Falcó. Doctor in Chemistry (Institut Químic de Sarrià) and MBA (Universitat de Barcelona).
Josep Lluís has 21 years of experience in the biomedical sector. He has worked for big pharma companies (Sanofi), mid-size pharmas
(Ferrer Grupo), small biotechs (Hospital spin-off), Tech Transfer Offices (Fundació Bosch i Gimpera) and Consulting firms (Antares
Consulting and Asphalion). He has also been associate professor at IQS.
His experience is based in Healthcare Strategy, Technology Transfer, Fundraising of start-up companies, Business Development, Marketing,
Market Access, Reimbursement and Regulatory Affairs.
Josep Lluís has founded 4 companies. He currently serves as board member for 5 start-up companies and he is mentor of several
entrepreneurs. In addition in the last 5 years he has been involved in 11 private fundraising processes and he has contributed to raise 42
million euros for his clients.
The projects in which Josep Lluís has been involved are based in small chemical entities, biologicals, diverse medical devices, in vitro
diagnostics, nutraceuticals and cosmetics.
The therapeutic areas where he has recently worked are Oncology, Central Nervous System, Cardiovascular, Ophthalmology, Orthopedics,
Traumatology, HIV, Microbiome, Antibacterials and Immunomodulation.
He has global knowledge of drug/device development, having worked in Discovery, Preclinical and Clinical phases, Marketing and Post-
Marketing.
Josep Lluís Falcó
Managing partner and CEO He takes part of programs such as Caixa Impulse and EIT Health programs, participating as reviewer, mentor and professor.
jlfalco@genesis-biomed.com The entrepreneurial spirit runs through his veins. He has founded GENESIS Biomed to help other entrepreneurs and research centers in
their current projects.
GENESIS Biomed - Corporate Presentation 1401 Corporate Presentation of GENESIS Biomed
A highly committed team
Natalia de la Figuera. PhD in Chemistry, Master in Project Management, PMP®
Natalia has developed her professional experience both in academic (CSIC Madrid and Barcelona) and in the
pharmaceutical industry: big pharma (Fresenius Kabi, Sanofi, Lilly, Merck-Serono), mid-size (Almirall, Palau Pharma)
and start-ups (Ojer Pharma, ImmunNovative Developments, Enantia).
She has worked in different positions in areas as project management, regulatory affairs, R & D and Quality among
others.
The main therapeutic areas on which she has been involved were oncology, central nervous system, anti-inflammatory,
antibacterial, autoimmune diseases and cardiovascular.
From 2015 she has been focused mainly in project management, broadening her knowledge on economic-
administrative monitoring and controlling, changes request and dissemination results of projects.
During her last job in the FSJD (Fundació Sant Joan de Déu) she was involved on public funding projects, some of them
collaboratives, allowing her to acknowledge another health environment.
Natalia de la Figuera She joins GENESIS Biomed in April 2019. She is a passionate of improving health and quality life for patients
Managing partner and COO
ndelafiguera@genesis-biomed.com
GENESIS Biomed - Corporate Presentation 1501 Corporate Presentation of GENESIS Biomed
A highly committed team
Jordi Ortiz. MSc in Chemistry, Biochemistry field (Universitat de Barcelona)
He completed his Master Thesis in Cation-induced aggregation and fusion of N-acyl-N-methylphosphatidyl-
ethanolamine liposomes and continued his research by studying the lipid-protein interaction.
In 1994, he joined the pharmaceutical industry and has occupied several positions, always in the R&D area (from
Discovery to Clinical phases). He has worked in Sanofi, Ferrer and Spherium Biomed. In this last company he has hold
the position of Senior Project Manager working in several projects from the discovery phase until the clinical research
phase.
He has an extended experience in several management positions in regulated analysis laboratories and as project
manager with both large and small molecules.
During the last years, he has been working in Autoinmune Diseases, Muscle recovery, ALS, Oncology Mucositis and
Acute Kidney Injury.
Jordi has also a deep expertise in European public fundraising and in Business Development activities, all of them
related to the projects in which he has participated.
Jordi Ortiz
Senior Consutant He joins GENESIS Biomed in March 2019. He is a passionate of biomedical innovations of academic origin in order to
jortiz@genesis-biomed.com accelerate their transition to the market.
GENESIS Biomed - Corporate Presentation 1601 Corporate Presentation of GENESIS Biomed
A highly committed team
Carles Taulé, BSc in Pharmacy (Universitat de Barcelona) and Master in Management of Biomedical Companies
(CESIF).
After several years as intern in Pharmacy Offices, in 2015 completes his Master Thesis in: “Role of Gram-positive
vesicles in the acquired resistance mechanisms of staphylococcal biofilms” in Department of Biomaterials,
Sahlgrenska Academy, University of Gothenburg (Sweden). In 2017 he has been involved in several technology
transfer projects at Fundació Bosch i Gimpera.
Carles Taulé
He joins GENESIS Biomed in September 2017. With a high entrepreneurial spirit, Carles is focused in the creation,
Consultant valorization and fundraising of spin-off and start-up companies in the biomedical environment.
ctaule@genesis-biomed.com
BSc in Biotechnology (Universitat Autònoma de Barcelona, 2012), BSc in Biochemistry (Technische Universität
Hamburg-Harburg, 2013) and Master in Pharmaceutical Industry and Biotechnology (Universitat Pompeu Fabra,
2015).
Berta has worked for 2 years at the Tech Transfer Office of IDIBELL (Institut d'investigació Biomèdica de Bellvitge).
Her fields of expertise are project management, fundraising and technology transfer. Previously, she worked as an
intern at some R&D laboratories (Esteve, Charité, Humboldt University of Berlin and IMIM).
Berta Borràs She joins GENESIS Biomed in May 2018. Science is her passion and she seeks to help entrepreneurs start their own
Consultant business.
bborras@genesis-biomed.com
GENESIS Biomed - Corporate Presentation 1701 Corporate Presentation of GENESIS Biomed
A highly committed team
BSc in Biology (Universitat de Barcelona, 2013) and Master in Genetics and Genomics (Universitat de Barcelona,
2014).
In the lasts three years Mireia has worked as research assistant in various stem cell projects in the field of heart and
and kidney differentiation in IBEC (Institut de Bioenginyeria de Catalunya).
She joins GENESIS Biomed in June 2018. She loves science and looks forward to support the creation of new start-
ups in the biomedical field.
Mireia Samitier
Consultant
msamitier@genesis-biomed.com
BSc in Biotechnology (Universitat de Vic, 2011) and Master in e-Health (Universitat Oberta de Catalunya, 2015).
In the last two years Gisela has worked in the Tech Transfer and Innovation Office of Sant Pau Research Institute,
with expertise in IP management and business development. She has three years of previous experience in e-Health
Project Manager as well as QMS Responsible at an ICT SME for the health sector.
She joins GENESIS Biomed in September 2018. Passionate about e-health and biotechnology, she seeks to help
entrepreneurs to bring innovation to society.
Gisela Gallego
Consultant
ggallego@genesis-biomed.com
GENESIS Biomed - Corporate Presentation 1801 Corporate Presentation of GENESIS Biomed
A highly committed team
BSc in Biomedical Sciences (Universitat de Lleida, 2018) and Master in Management of Biotech companies at
CESIF.
Anna has experience as a research assistant in some different areas (biophysics, neuroscience and pathological
anatomy) in laboratories belonging to University of Pécs (Hungary), Universitat de Barcelona and HUAV Lleida. She
developed her final dissertation in IDIBAPS (Barcelona) studying the role of nutrigenomics in the progression of type
2 diabetes. She has finished a Master in Management of Biotech companies (CESIF), acquiring all the necessary
knowledge to develop her skills in the sector.
Anna Miró
Consultant Anna joins GENESIS Biomed in March 2019. She is willing to assist entrepreneurs in the establishment of their new
amiro@genesis-biomed.com innovative companies.
BSc in Biotechnology (Universitat de Barcelona, 2019) and MSc in Technology and Management of Biotech
companies (CESIF, 2020).
Alberto has experience as an undergraduate researcher in laboratories belonging to the University of Cologne
(Germany). He developed his Bachelor´s Thesis in CECAD (Cologne) studying ubiquitin and its effect on cellular
regulation and homeostasis under stress conditions, under the supervision of Dr. Mafalda Escobar-Henriques Dias.
Eager to acquire and develop his career in Biotech based companies' management he is attending to a Master´s
Degree in Technology and Management of such companies at CESIF. Alberto joins GENESIS Biomed in January 2020.
Alberto Rodríguez With his scientific background he looks forward to help in the development of spin-off and start-up companies,
Consultant trainee considering technology transfer as a tool of innovation.
arodriguez@genesis-biomed.com
GENESIS Biomed - Corporate Presentation 1901 Corporate Presentation of GENESIS Biomed
A highly committed team
BSc in Biotechnology(Universitat de Barcelona, 2019) and Master in Management of Biotech companies at CESIF.
Mariona studied Biotechnology and is currently attending a Master in Management of Biotech companies at CESIF in
order to assist the establishment and growth of small biotechnological companies. She performed her final degree
project in the Spin-off DBGen Ocular Genomics where she performed tasks related to the optimization of Inherited
Retinal Disorders’ genetic diagnose.
She joins GENESIS Biomed in January 2020. She is passionate of Life Sciences and looks forward to support spin-off
Mariona Costa and start-up creation.
Consultant trainee
mcosta@genesis-biomed.com
Degree in Journalism (Universitat Autònoma de Barcelona), postgraduate course in Medical Communications (Universitat Pompeu
Fabra), Translation Studies at Universitat Autònoma and University of Glasgow and Digital Marketing in ESADE.
Teresa has over 15 years experience as a reporter and communications specialist, mainly working for the healthcare sector, with a focus
on digital health. In the last years she has worked for organizations such as Novartis, HIMSS Europe, Patient Power, UOC eHealth
Center, UpToDate, Among Doctors, Mobile World Capital.
Teresa’s areas of expertise include digital communications, social media, communications strategy, content production, digital
marketing, media relations, PR, Patient Engagement. She has a large network of contacts in the health sector at a national and
Teresa Bau international level. She is a member of the Catalan Association of Scientific Communication and the Journalists College.
Communications Manager
Teresa joins GENESIS Biomed in January 2020.
tbau@genesis-biomed.com
GENESIS Biomed - Corporate Presentation 2001 Corporate Presentation of GENESIS Biomed
Our Scientific Advisory Board
Dr. Josep Tabernero Dr. Pere Ginés
Chairman of the Board – Expert in Oncology Expert in Hepatology
Chairman of Liver Unit, Hospital Clinic Barcelona; Full Professor
Head of the Department of Medical Oncology in Vall d’Hebrón
of Medicine, University of Barcelona; Director of Liver
University Hospital; Director of the Vall d’Hebrón Research
Transplantation; Head of Research Group, IDIBAPS and
Institute in Oncology.
CIBEReHD.
Dr. Rafael Cantón Dr. José Luís Molinuevo
Expert in Infectious Diseases Expert in Neurology
Head of the Clinical Microbiology Department at the University Scientific director and Head of the Clinical, Biomarker and Risk
Hospital Ramón y Cajal; associated Professor of Clinical Factors Research Group at the Barcelonabeta Research Centre
Microbiology at Complutense University of Madrid. (BBRC); associate professor in University Pompeu Fabra.
Dr. Francisco Fernández Avilés Dr. Rafael Simó
Expert in Cardiology Expert in Endocrinology
Full Professor of Cardiovascular Medicine at the Complutense Chair of the Division of Endocrinology and Nutrition at Vall
University (UCM); Chairman of the Department of Cardiology in d’Hebron University Hospital; Director of Diabetes and
the University Hospital Gregorio Marañón of Madrid; Scientific Metabolism Research Unit at Vall d’Hebron Research Institute
Director of the Spanish Network Centre for Cardiovascular (VHIR); Professor of Medicine & Endocrinology at the
Research (CIBERCV). Autonomous University of Barcelona.
GENESIS Biomed - Corporate Presentation 2101 Corporate Presentation of GENESIS Biomed
The needs we understand for a fundraising process with a startup. Our Methodology
For a fundraising process with a given startup, there are some important steps to accomplish prior starting the
roadshow. For that purpose, an Interim CEO should lead the fundraising process, including:
• Business plan preparation and cash need dimension
• Fundraising strategy set up
• Selection of the most suitable VCs for the fundraising, taking care of:
• Lifecycle of the current funds
• Lifecycle of the invested projects
• Portfolio of invested projects
• Preparation of the roadshow with investors
• Starting of the fundraising process:
• Non-confidential approaches and contacts
• First TCs and meetings
• Signature of NDA
• Starting of building the syndicate up
• Negotiation of the Term Sheet
• Creation of a Data Room and coordination of the Due Diligence
• Negotiation of the Investment and Shareholders Agreement
• In the meanwhile, identification of the full-time CEO that will join the spin-off company
GENESIS Biomed - Corporate Presentation 2201 Corporate Presentation of GENESIS Biomed
Our Methodology. Which are the 10 success factors to learn and implement? (1/5)
1. Market Analysis
• Current unmet medical need
• Epidemiology
• Determination of market size
• Description of market trends
• Analysis of main players in the market (commercial products)
• Description of the future competitors (development projects)
2. Competitive positioning
• Analysis of main features of current and future competitors
• Price analysis
• Business model analysis
• Market share analysis
• Voice of Customer and Cost-effectiveness analysis
• Competitors matrix
GENESIS Biomed - Corporate Presentation 2301 Corporate Presentation of GENESIS Biomed
Our Methodology. Which are the 10 success factors to learn and implement? (2/5)
3. Proof of Concept results
• Complete list and description of studies done till date
• Main results obtained and conclusion analysis
• Studies to be conducted in the future
• Current agreement with the Main Institution
• Outsourced studies and external collaborations
• R+D Gantt chart
4. Intellectual Property
• List of filed patents till date
• Analysis of the current situation of each filed patent
• List of potential future patents in the project
• Freedom to operate analysis
• License Agreement from the Institutions
• IP strategy of the company
GENESIS Biomed - Corporate Presentation 2401 Corporate Presentation of GENESIS Biomed
Our Methodology. Which are the 10 success factors to learn and implement? (3/5)
5. Regulatory Strategy
• Regulatory framework for the current project
• Analysis of the corresponding guidelines and directives
• Current regulatory considerations
• Future trends and regulatory changes
• Regulatory strategy and validation
• Regulatory roadmap
6. Development plan
• List of all needed studies for the development of the product
• Gantt chart for the whole development process
• Identification of main milestones
• Measurement of timelines
• Identification of potential outsourced partners
• Prediction of associated costs
GENESIS Biomed - Corporate Presentation 2501 Corporate Presentation of GENESIS Biomed
Our Methodology. Which are the 10 success factors to learn and implement? (4/5)
7. Internal team of de company
• Existing team and initial roles
• Presence of a full-time CEO
• Complete job description for all needed roles in the future
• Organigram analysis and Headcount evolution in the company
• Analysis of salaries and ESOP for internal staff
• Partners Agreement, Governance and Reserved matters
8. External team
• Profiles needed for the Scientific Advisory Board
• Design of the Board of Directors
• Identification of the Chairman
• Identification of suitable outsourced roles and service providers
• Analysis of costs and quotations
• Design of ESOP for key external people
GENESIS Biomed - Corporate Presentation 2601 Corporate Presentation of GENESIS Biomed
Our Methodology. Which are the 10 success factors to learn and implement? (5/5)
9. Financial Plan
• Definition of the Business Model of the company
• Quantification of the global cash need
• General Risk Analysis and mitigation plan
• Main financial milestones and Identification of Tranches
• Fundraising strategy for Investors and Exit scenario analysis
• Valuation of the company and Cap Table analysis
• Preparation of the Financial Plan: CF, P&L and BS
10. Strategy and Fundraising negotiation
• Selection of the most suitable investors
• Preparation of the slide deck of the company
• Roadshow and first meetings round
• Building the syndicate up
• Analysis and negotiation of the Term sheet
• Preparation of Data room for Due diligence
• Negotiation of the Investment Agreement and Partners Agreement
• Closing of the Round
GENESIS Biomed - Corporate Presentation 2701 Corporate Presentation of GENESIS Biomed
Last success cases in fundraising. Our Track record
Signed deals Sector Round size Year Investors
AptaTargets Pharma 4,5 M€ 2017 Caixa Capital Risc, Inveready
Anaconda Biomed Medtech 15 M€ 2017 Ysios, Omega, Innogest, BSabadell
Peptomyc Biotech 4,2 M€ 2017 ALTA Life Sciences, Healthequity
GlyCardial Diagnostics IVD 3,1 M€ 2017 Caixa Capital Risc, Healthequity
MJN Neuroserveis Medtech 750 k€ 2018 Ship2B and Family Offices
Cornea Project IVD 300 k€ 2018 Industrial partner
Corify Care Medtech 1 M€ 2019 Family Office and EU Funds
Oxolife Pharma 300 k€ 2019 Family Office
Cornea Project IVD 300 k€ 2019 Family Office
LiverScreen Project Medtech 8,5 M€ 2019 EU Funds
CreatSens IVD 750 k€ 2019 EU Funds
ABLE Human Motion Medtech 2,5 M€ 2019 EU Funds
GENESIS Biomed - Corporate Presentation 2801 Corporate Presentation of GENESIS Biomed
Our success stories in fundraising
• Medtech project: stratification of patients suffering from atrial fibrillation
• 1 M€ raised in January 2019
• Investors: Family offices and EU funds
• Pharma project: new aptamer for ischemic stroke
• 2,7 M€ raised in May 2017
• Investors: Caixa Capital Risc and Inveready
• Medtech project: new catheter for thrombectomy
• 15 M€ raised in May 2017
• Investors: Ysios, Omega, Innogest, Banc Sabadell
• Biotech project: recombinant protein for NSCLC and TNBC
• 4,2 M€ raised in July 2017
• Investors: ALTA Life Sciences and Healthequity
• IVD project: new biomarker for cardiovascular ischemia
• 2,4 M€ raised in October 2017
• Investors: Caixa Capital Risc and Healthequity
GENESIS Biomed - Corporate Presentation 2901 Corporate Presentation of GENESIS Biomed
Current projects in fundraising process
Company sector Product Indication Round size
Ophtalmology IVD Cornea disorders 3,6 M€
Cardiovascular Medtech Atrial fibrillation 15 M€
Nephrology IVD Renal failure 300 k€
Women’s health Pharma Fertility 8,1 M€
Gastrointestinal Medtech Chronic Constipation 5 M€
Ophtalmology Pharma Retinitis pigmentosa 500 k€
GENESIS Biomed - Corporate Presentation 3002
Presentation of our new fund GENESIS Ventures
GENESIS Biomed - Corporate Presentation 3102 Presentation of GENESIS Ventures
Context and need for a New Fund in Tech Transfer (1/2)
Activities for GENESIS Biomed during this year
GAP Business plan Fundraising General
Interim CEO
Projects need to be valorised preparation support support…
Month -12… Month -6 Month 0 Month 6 Month 12
GENESIS Biomed starts
After the work done by The startup is founded
working with a client
GENESIS, the project is and the financial round
coming from hospital,
ready to start roadshow is closed. The project
university or research
with VC investors development starts…
center
GENESIS Biomed - Corporate Presentation 3202 Presentation of GENESIS Ventures
Context and need for a New Fund in Tech Transfer (2/2)
Questions related to this GAP:
1. All researchers lack of funds for the valorisation
of their projects
2. Usually the researchers are not business
oriented when deciding which studies to
perform
3. With funds & advise, the GAP can be shortened
and the project can be ready to start the
fundraising process in advance
GENESIS Biomed - Corporate Presentation 3302 Presentation of GENESIS Ventures
Lifecycle and portfolio management for GENESIS Ventures
GENESIS Ventures The spin-off is The series A is closed with
invests in the founded and GV VC investors. GV remains as
research project becomes shareholder shareholder until the exit
Period of time in which the ticket will be devoted to the valorisation of the Period of time in which GENESIS Biomed will support the spinoff (potential GENESIS’ client)
research project (new experiments to generate new results to increase the project value) in the fundraising process to finally close a series A with Venture Capital
GENESIS Biomed - Corporate Presentation 3402 Presentation of GENESIS Ventures
Investment policy with a given identified project that will become spin-off in 1 year
Phase 1: Pre-foundation of the spin-off Phase 2: Foundation of the spin-off
Our Total Fund: 2,0 M€ After the investment period, the spinoff company should be founded. If the spinoff is
not founded and the project is licensed to a third party, the Investment Agreement
regulates the return to GENESIS Ventures (via upfront and/or royalties).
Tickets*: 25.000 – 100.000 €
In the foundation, GENESIS Ventures acquires the corresponding shares committed
Investment Agreement is signed in the Investment Agreement. Our policy is not to become a major shareholder.
with Research Center and
Research Group
After the foundation, GENESIS Biomed will help the new spinoff (becoming potential
GENESIS’ client) in the fundraising process in order to close a series A with Venture
Max. time to found NewCo*: 1 year Capital investors.
GENESIS Biomed will manage the
projects and will inform the Exit scenario: the standard exit scenario for Venture Capital once the Company is
Investments Committee acquired or the project is out-licensed to a third party.
* Orientative figures. These will be fixed in a case-by-case basis
GENESIS Biomed - Corporate Presentation 3502 Presentation of GENESIS Ventures
Our invested projects till date
ELEM ADmit Tx Aptamer Quality MOWOOT
NeuroHeal Pharma
Spinoff UAB
Spinoff BSC-UPC Spinoff IDIBELL project Start-up
Spinoff IRYCIS Medtech
Developing a new Developing a new Spinoff Karolinska Developing a new
Developing a new
software for IVD for early Developing a new solution for SCI
therapy for
virtualization of detection of aptamer for Breast Developing a new and chronic
neuroregeneration
human organs Alzheimer Disease Cancer CDSS constipation
Ticket: 150.000€
Ticket: 75.000€ Ticket: 100.000€ Ticket: 50.000€ Ticket: 100.000€ Ticket: 100.000€
LIMNO Aortyx
Spinoff CSIC
Spinoff IQS
SHBG ABLE CreatSens DropLite
Spinoff VHIR Spinoff UPC Spinoff URV Spinoff ICFO
Developing a new
Developing a new
therapy for Developing a new Developing a new Developing a new Developing a new
device for aortic
retinitis therapy for obesity exoskeleton for SCI IVD for CKD IVD for AH
aneurism
pigmentosa
Ticket: 50.000€ Ticket: 50.000€ Ticket: 50.000€ Ticket: 50.000€
Ticket: 100.000€
Ticket: 125.000€
GENESIS Biomed - Corporate Presentation 36©GENESIS Biomed
Barcelona Office:
Barcelona Science Park
Tower I, offices 3B01-03-05-06 GENESIS Biomed is member of:
Baldiri Reixac 4-8
08028 Barcelona
+34 93 403 58 53
Madrid Office:
Velázquez 25, 2º A
28001 Madrid
contact@genesis-biomed.com
GENESIS Biomed - Corporate Presentation 37You can also read
